Fibromyalgia global drug forecast and market analysis to 2023

PharmaPoint: Fibromyalgia ? Global Drug Forecast and Market Analysis to 2023

Single User License - $10995 Site User License - $21990 Corporate User License - $32985 Publication Date - May 2015 Pages - 223 To know more details, email to debora@reportstack.com

Contact: debora@reportstack.com Reportstack Market Research

Summary • The fibromyalgia market is relatively new and not yet established. Three drugs currently dominate the sales across the 7MM and form the core treatment options; Lyrica, Cymbalta and Savella are all approved in the US while only the former is approved in Japan. Since these drugs are also available in the 5EU for other indications, they are prescribed as off-label therapies. A handful of other genericized products also provide off-label usage including antidepressants, anti-epileptics, opioids and muscle relaxants. Although Lyrica, Cymbalta and Savella can provide an effective treatment regimen, there are ample opportunities for the development of alternative treatment choices which can expand the medications available to patients, providing improvement in efficacy, safety and compliance. By 2023, there will be four new entrants to the market (Lyrica CR, TNX-102 SL, DS-5565 and TD-9855).

Contact: debora@reportstack.com Reportstack Market Research

Scope • Overview of fibromyalgia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

• Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the fibromyalgia therapeutics market.

• Pipeline analysis: focus on the four late-stage pipeline drugs discussing emerging trends as well as overview of earlier phase drugs.

• Analysis of the current and future market competition in the global fibromyalgia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Contact: debora@reportstack.com Reportstack Market Research

Key Findings • The main driver of the expansion of the fibromyalgia market will be the introduction of four new therapies across the seven major markets. • The biggest barrier for the introduction of new therapies will be patent expirations of the leading brands marketed for fibromyalgia, which will result in an increase of generics, and which may negatively impact revenue from branded drugs that are expected to launch in the forecast period. • The concerns of reducing healthcare costs as part of government austerity measures, particularly in Europe, which will impede market growth. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively.

Contact: debora@reportstack.com Reportstack Market Research

Companies Mentioned Daiichi Sankyo Eli Lilly Forest Laboratories/Actavis Innovative Med Concepts Meda Meiji Seika Pharma Pfizer Switch Biotech Theravance Biopharma Tonix Pharmaceuticals Contact: debora@reportstack.com Reportstack Market Research

If you are interested...

Contact : Debora White Email: debora@reportstack.com Ph:+1-888-789-6604 http://www.reportstack.com

Contact: debora@reportstack.com Reportstack Market Research